A 2-part, Randomised, Placebo-controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of AZD8871 Delivered by Inhalation in Asthmatic and Chronic Obstructive Pulmonary Disease (COPD) Subjects

Trial Profile

A 2-part, Randomised, Placebo-controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of AZD8871 Delivered by Inhalation in Asthmatic and Chronic Obstructive Pulmonary Disease (COPD) Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs AZD 8871 (Primary) ; Indacaterol; Tiotropium bromide
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 05 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
    • 05 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top